Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

Add Yahoo as a preferred source to see more of our stories on Google. Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...

DexCom's not just a diabetes company anymore. They're at the forefront of wearable health tech, blurring the lines between medicine and lifestyle. DexCom might not be the flashiest stock, but their ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...

Shares of DexCom DXCM lost almost 3% on Jun 3, probably due to concerns about a rise in competition for its recently approved Stelo as the FDA approved a competing product. The FDA approval for Stelo ...

While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a ...